Where world-class innovation meets dermatology

Latest news

Sofdra ™ (sofpironium) topical gel, 12.45% is now available in the US

Our lead dermatology product, Sofdra , is approved for use by the US Food and Drug Administration (FDA).

Prescribing Information Patient Product Information

Visit Sofdra.com

Read press release

Mature pipeline of dermatology and antimicrobial products—including Sofdra, an FDA-approved treatment.

Explore products & pipeline

World-class team with extensive dermatology drug development and commercialisation expertise.

Learn more about us

Global healthcare innovator, poised to transform the most underserved and lucrative markets.

Visit the investor centre

Explore products & pipeline

Learn more about us

Visit the investor centre

Innovators and commercial leaders in dermatology

Here at Botanix, we are at the forefront of dermatological innovation. With a world-class team and significant capital, we are committed to addressing common yet underserved skin diseases and infections.

As an ASX-listed company, we are in a prime position to develop and commercialise groundbreaking treatments across broad markets, all while adhering to the highest clinical standards set by the US FDA.

View products & pipeline

Check out our latest news

November 25, 2025

Botanix expresses thanks to valued shareholders and other significant

November 3, 2025

We share the International Hyperhidrosis Society’s belief that ‘together

October 16, 2025

Quarterly Update Webinar October 20 | Registration Open

June 12, 2024

Botanix has submitted the last label materials to the US Food & Drug Administration (FDA) for Sofdra™ a pending prescription treatment for excessive underarm sweating.